Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.

MLA

Cui, Wen, et al. “Arsenic Trioxide at Conventional Dosage Does Not Aggravate Hemorrhage in the First-Line Treatment of Adult Acute Promyelocytic Leukemia.” European Journal of Haematology, vol. 100, no. 4, Apr. 2018, pp. 344–50. EBSCOhost, https://doi.org/10.1111/ejh.13018.

APA

Cui, W., Wang, J., Nie, R.-M., Zhao, L.-L., Gao, M.-Q., Zhu, H.-M., Chen, L., Hu, J., Li, J.-M., Shen, Z.-X., Wang, Z.-Y., Chen, S.-J., Chen, Z., Wang, K.-K., Xi, X.-D., & Mi, J.-Q. (2018). Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia. European Journal of Haematology, 100(4), 344–350. https://doi.org/10.1111/ejh.13018

Chicago

Cui, Wen, Jin Wang, Rui-Min Nie, Ling-Ling Zhao, Meng-Qing Gao, Hong-Ming Zhu, Li Chen, et al. 2018. “Arsenic Trioxide at Conventional Dosage Does Not Aggravate Hemorrhage in the First-Line Treatment of Adult Acute Promyelocytic Leukemia.” European Journal of Haematology 100 (4): 344–50. doi:10.1111/ejh.13018.